Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea
Conditions
Interventions
Brimonidine 0.33% gel (Br)
CD07805/47 (Br) placebo gel
+2 more
Locations
13
United States
Fort Smith, Arkansas, United States
Rogers, Arkansas, United States
Sacramento, California, United States
Orlando, Florida, United States
Omaha, Nebraska, United States
New York, New York, United States
Start Date
December 1, 2015
Primary Completion Date
September 1, 2016
Completion Date
September 1, 2016
Last Updated
February 18, 2021
NCT07106957
NCT06466018
NCT04108897
NCT07250165
NCT04214483
NCT06969300
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions